Barclays PLC Delcath Systems, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Barclays PLC holds 55,996 shares of DCTH stock, worth $500,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,996
Previous 53,783
4.11%
Holding current value
$500,044
Previous $732,000
17.9%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DCTH
# of Institutions
130Shares Held
13MCall Options Held
133KPut Options Held
159K-
Vanguard Group Inc Valley Forge, PA1.66MShares$14.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$6.14 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT666KShares$5.95 Million0.29% of portfolio
-
State Street Corp Boston, MA621KShares$5.55 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA570KShares$5.09 Million0.97% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $76.8M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...